Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 137, Issue 1, Pages 116-126Publisher
WILEY
DOI: 10.1002/ijc.29366
Keywords
immunotherapy; B-cell lymphoma; CD20 antigen; CD4 T cells; splicing
Categories
Funding
- Ligue contre le cancer
- ICB network of the University of Franche-Comte
- Conseil Regional de Franche-Comte
- Agence Nationale de la Recherche (Labex LipSTIC) [ANR-11-LABX-0021]
- Fondation de France
- Etablissement Francais du Sang
Ask authors/readers for more resources
Cancer-specific splice variants gain significant interest as they generate neo-antigens that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cells and in B cell lymphomas, is subject to an alternative splicing named D393-CD20 leading to loss of membrane expression of the spliced isoform. D393-CD20 expression is detectable in transformed B cells and upregulated in various lymphoma B cells. In this study, we show that D393-CD20 is translated in malignant B cells and that D393-CD20 specific CD4 T cells producing IFN- are present in B-cell lymphoma patients. Then, we have investigated whether the 20mer D393-CD20 peptide spanning the splicing site might be targeted by the immune system and we have shown that D393-CD20-specific CD4 Th1 clones could directly recognize malignant B cell lines and kill autologous lymphoma B cells indicating that D393-CD20-derived epitopes are naturally processed and presented on tumor cells. Finally, D393-CD20 peptide-based vaccination induced specific CD8 and CD4 T cell responses in HLA-humanized transgenic mice suggesting the presentation of D393-CD20 derived peptides on both HLA Class-I and -II. These findings support further investigations on the potential use of D393-CD20 directed specific immunotherapy in B cell malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available